ASCO 2024

ASCO 2024
May 31-June 04, 2024
Chicago, IL

American Society of Clinical Oncology 2024.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (7)

    Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50%: Cohort A of EVOKE-02

    • Author(s): Patel, J
    • trodelvy
    • Oncology
    • Poster

    EDGE-Gastric Arm A1: Phase 2 Study of Domvanalimab, Zimberelimab, and FOLFOX in First-Line Advanced Gastroesophageal Cancer

    • Author(s): Janjigian, Y
    • domvanalimab
    • zimberelimab
    • Oncology
    • Oral

    Pooled Safety Analysis of Sacituzumab Govitecan in Multiple Solid Tumor Types

    • Author(s): Rugo, H
    • trodelvy
    • Oncology
    • Poster

    ARC 9: A Randomized Study to Evaluate Etrumadenant Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer

    • Author(s): Wainberg, Z
    • etrumadenant
    • Oncology
    • Oral

    Genomic Alterations in DNA Damage Response Genes in HR+/HER2- Metastatic Breast Cancer and Impact on Clinical Efficacy with Sacituzumab Govitecan: Biomarker Results from TROPiCS-02 Study

    • Author(s): Bardia, A
    • trodelvy
    • Oncology
    • Poster

    VELOCITY-Lung Substudy-03: A Phase 2 Study Evaluating Safety and Efficacy of Domvanalimab + Zimberelimab or Zim Alone in Combination with Chemotherapy in the Neoadjuvant Phase and Dom+Zim 

    • Author(s): Sadiq, A
    • domvanalimab
    • zimberelimab
    • Oncology
    • Poster

    Sacituzumab Govitecan vs Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy and PD(L)-1 Inhibitors: Primary Results from the Phase 3 EVOKE-01 Study

    • Author(s): Paz-Ares, L
    • trodelvy
    • Oncology
    • Oral